SCHEDULE: Allogene Therapeutics: Dr. Belldegrun's 5.7% Stake

Dr. Arie Belldegrun and affiliated entities report a combined beneficial ownership of 5.7% in Allogene Therapeutics, Inc. common stock.

Summary

• Dr. Arie Belldegrun, along with affiliated entities, collectively holds 12,605,894 shares of Allogene Therapeutics, Inc. common stock.
• This aggregate ownership represents 5.7% of the company's outstanding common stock.
• The percentage is calculated based on 218,730,809 shares outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 13, 2025.
• Dr. Belldegrun's reported beneficial ownership includes 3,243,004 shares issuable within 60 days of June 30, 2025, upon the exercise of stock options.
• His reported ownership also encompasses shares held by Bellco Legacy IV LLC (4,710,120 shares), Bellco Legacy LLC (539,867 shares), Vida Ventures LLC (1,798,163 shares), Vida Ventures III, L.P. (1,720,172 shares), and Vida Ventures III-A, L.P. (3,965 shares), all of which he manages or is a Senior Managing Director of.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a significant and stable stake by a key individual and affiliated investment entities. It does not contain operational or financial performance data to assess positive or negative sentiment beyond the ownership structure itself, thus leaning neutral to slightly positive due to insider alignment.

Positives

• Significant beneficial ownership by a key individual (Dr. Arie Belldegrun) and associated investment entities, indicating continued alignment with shareholder interests.
• Inclusion of exercisable stock options in Dr. Belldegrun's beneficial ownership suggests potential for increased direct stake.

Future Outlook

NA

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

This filing reflects a significant ownership stake by a prominent individual and associated venture capital firms in the biotechnology sector. Such filings are common for founders, executives, and early investors in biotech companies like Allogene Therapeutics, which often rely on venture capital funding and strategic partnerships.

Comparison to Industry Standards

• Beneficial ownership percentages of 5% or more by individuals or investment groups are standard thresholds requiring Schedule 13G filings.
• Dr. Belldegrun's 5.7% stake is a notable insider/institutional holding, common in early-stage or growth-oriented biotech companies where founders and venture capital firms maintain significant influence.
• No specific comparable companies, projects, or results are mentioned in the filing to allow for a direct comparison of operational or financial performance.

Related Party Transactions

• Dr. Arie Belldegrun's beneficial ownership includes shares held by Bellco Legacy LLC and Bellco Legacy IV LLC, which he manages or controls through trusts.
• His beneficial ownership also includes shares held by Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P., where he serves as a Senior Managing Director.
• Dr. Belldegrun disclaims beneficial ownership of shares held by Vida, Vida III, and Vida III-A, except to the extent of any pecuniary interest, and for Section 13(d) purposes.

Stakeholder Impact

• Shareholders: The significant beneficial ownership by Dr. Arie Belldegrun and affiliated entities suggests strong alignment of interests between a key insider/investor and the company's performance, which can be viewed positively by other shareholders.
• Management: The continued substantial stake by a Senior Managing Director of Vida Ventures and manager of Bellco Legacy entities indicates ongoing commitment and potential influence on strategic direction.

Key Dates

Recommendation

This Schedule 13G filing primarily reports beneficial ownership and does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. The significant and stable ownership by Dr. Arie Belldegrun and affiliated entities suggests continued insider confidence, which supports a 'hold' stance for existing investors. New investors would need to consider broader company fundamentals and market conditions beyond this ownership disclosure.

Keywords

Allogene Therapeutics, Arie Belldegrun, Schedule 13G, beneficial ownership, common stock, institutional ownership, insider ownership, biotechnology, pharmaceutical